Clinical Trial Update: A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody [Phase 2, Phase 3]

View source ↗

Summary

Long-term follow-up study of HLH patients treated with emapalumab (anti-IFNγ) across Phase 2/Phase 3 completed with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Emapalumab (emapalumab)

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Hemophagocytic Lymphohistiocytosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-06-28